Werewolf Therapeutics (HOWL) and Ambros Therapeutics Join Forces in Strategic Merger
Werewolf Therapeutics and Ambros Therapeutics announce an all-stock merger and a $150 million private placement, focusing on oncology.
TG Therapeutics (TGTX) Sees Stock Surge Amid Acquisition Buzz
TG Therapeutics is gaining traction as speculation about a potential acquisition heats up, fueled by its drug BRIUMVI's FDA approval.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Werewolf Therapeutics and Ambros Therapeutics Join Forces: Implications for Oncology Investors
A strategic merger between Werewolf and Ambros Therapeutics aims to enhance oncology therapeutics, raising $150 million …
Bunker Hill Mining and Silver47 Merge: A New Force in North American Silver and Critical Minerals
Bunker Hill Mining and Silver47 have merged in a $163M all-stock deal, positioning themselves as leaders in critical min…
Bristol Myers Squibb's ZENBEXUS Approval: A Strategic Move in Oncology
Bristol Myers Squibb's ZENBEXUS receives FDA approval, marking a significant step in oncology and investor interest.
Ultragenyx's GENGLYCOS Approval: A Game Changer for Rare Disease Therapies
Ultragenyx's recent FDA approval for GENGLYCOS signals a significant shift in rare disease treatments.
Motorola Solutions Expands into Counter-Drone Technology: Key Takeaways from the $1.5 Billion Acquisition
Motorola Solutions' $1.5 billion acquisition of D-Fend Solutions positions the company at the forefront of counter-drone…
Ultragenyx Pharma's Surge: FDA Approval for GENGLYCOS and Its Market Implications
Ultragenyx Pharma's shares jumped ~14% following FDA approval for GENGLYCOS, highlighting its potential in the gene ther…
Moderna's Landmark Phase 3 Win: What It Means for MRNA and the Biotech Sector
Moderna's recent Phase 3 trial success has sent shockwaves through the biotech sector, propelling its stock and igniting…
Aurora Cannabis Faces Hostile Takeover: What It Means for Investors
Aurora Cannabis is confronted with a hostile takeover bid from Curaleaf, raising questions about the future of the North…
Merck's Breakthrough: Analysts React to Positive Drug Trial News
Analysts are optimistic about Merck's future after a 7.4% surge in shares following positive trial results.